ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 328.29% | -56.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 328.29% | -56.67% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 328.29% | -56.67% | |||
| SG&A Expenses | 26.81% | -0.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.45% | 14.11% | |||
| Operating Income | 35.75% | -50.80% | |||
| Income Before Tax | 35.36% | -50.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 35.17% | -50.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.17% | -50.80% | |||
| EBIT | 35.75% | -50.80% | |||
| EBITDA | 37.73% | -46.77% | |||
| EPS Basic | 37.89% | -50.71% | |||
| Normalized Basic EPS | 38.11% | -50.81% | |||
| EPS Diluted | 38.86% | -54.26% | |||
| Normalized Diluted EPS | 38.11% | -50.81% | |||
| Average Basic Shares Outstanding | 4.36% | 0.01% | |||
| Average Diluted Shares Outstanding | 4.36% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||